Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle.

Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle. The company ...

The what, now? you may ask, reading this title. The social life of cats? Cat owners may have some doubts about this very concept. But in the last decade or so, there has been an upsurge of more ...

If you've ever owned or cared for cats, you know that they tend to have their unique way of doing things and their individual temperaments. Some cats are attached to your hip while others don't ...

Last year, cat owner Chelsea, of Denver, Colorado, noticed that her "old lady cat" named Hari appeared to be slowing down and was struggling to keep up with her feline siblings. Hari was rescued ...

The firm thinks the pressure on Cytokinetics’ shares may be overdone given what the firm sees as a competitive profile for aficamten. Truist has a Buy rating and $70 price target on Cytokinetics ...

The firm says this news has “negative commercial readthroughs” for Cytokinetics, which has long-maintained aficamten’s differentiated molecular profile would justify a relatively improved ...

Elsewhere in the cardiovascular pipeline, Cytokinetics’ aficamten was submitted to regulators late last year. The hoped-for indication: symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a ...